CTMX
CytomX Therapeutics, Inc.
There isn't enough reported data to score CTMX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CTMX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
CTMX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTMX PE Valuation
CTMX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CTMX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CTMX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CTMX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.61 | -253% |
| Q2 2026 | -$0.61 | -209% |
| Q1 2026 | -$0.52 | -208% |
| Q4 2025 | -$0.15 | -139% |
| Q3 2025 | $0.40 | +122% |
| Q2 2025 | $0.56 | +273% |
| Q1 2025 | $0.48 | +129% |
| Q4 2024 | $0.38 | +$0.39 |
CTMX has swung to a loss: it lost $0.61 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CTMX on earnings quality, reporting a profit while its opponent remains loss making.
CTMX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7M | -72% |
| Q2 2026 | $1.4M | -92% |
| Q1 2026 | $10.3M | -80% |
| Q4 2025 | $663K | -98% |
| Q3 2025 | $6M | -82% |
| Q2 2025 | $18.7M | -26% |
| Q1 2025 | $50.9M | +23% |
| Q4 2024 | $38.1M | +43% |
CTMX's revenue has slid since its 2025 peak: $2M last quarter, down 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1392% | -1128 points |
| Q2 2026 | -1677% | -1670 points |
| Q1 2026 | -192% | -236 points |
| Q4 2025 | -4213% | -4259 points |
| Q3 2025 | -264% | -277 points |
| Q2 2025 | -6.9% | +27 points |
| Q1 2025 | 44% | +16 points |
| Q4 2024 | 46% | +49 points |
CTMX's operating margin was −1392% last quarter, down 1128 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CTMX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CTMX on profitability, with a higher operating margin.
CTMX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $16.1M | +$31.5M |
| Q2 2026 | -$18.1M | -$2.3M |
| Q1 2026 | -$25.5M | -$4.4M |
| Q4 2025 | -$23.4M | -$3.5M |
| Q3 2025 | -$15.4M | +$5.3M |
| Q2 2025 | -$15.8M | +$3.9M |
| Q1 2025 | -$21.2M | +$5M |
| Q4 2024 | -$20M | +$2.2M |
CTMX has burned cash in almost every quarter: −$51M over the past year, against −$72M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CTMX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTMX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +167K shares |
| 1 year | +33% | +54.1M shares |
| 3 years | +171% | +138M shares |
| 5 years | +236% | +154M shares |
| Available history | +383% | +174M shares |
CTMX has 219M diluted shares, up 33% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CTMX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CTMX Net Leverage
CTMX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CTMX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.8 | Neutral |
| Stochastic | 7.3 | Oversold |
CTMX's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CTMX PE vs Healthcare Sector
| Metric | CTMX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTMX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CTMX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.38 | 14% below |
| 20 week MA | $2.98 | 32% below |
| 50 week MA | $3.82 | 47% below |
| 100 week MA | $2.87 | 29% below |
| 200 week MA | $2.23 | 8.5% below |
CTMX is in a downtrend: it's below all five of its weekly moving averages, and 8.5% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CTMX on trend strength, trading above more of its moving averages.
CTMX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.54 | $7.42 | -13% |
| 2021 | $7.42 | $4.22 | -43% |
| 2022 | $4.22 | $1.55 | -63% |
| 2023 | $1.55 | $1.55 | 0% |
| 2024 | $1.55 | $1.07 | -31% |
| 2025 | $1.07 | $4.39 | +310% |
| 2026 YTD | $4.39 | $2.04 | -54% |
CTMX's yearly returns have swung widely, from +310% in 2025 to −63% in 2022. It's down 54% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CTMX on returns for 2026, with the stronger performance.